News Is BMS the next pharma takeover target? Speculation mounting that Pfizer and others could try for $90 bn plus merger
News Heart trial success will give Xarelto edge Xarelto aces outcomes trial and could have edge over Boehringer and BMS rivals.
News Innate and BMS' immunotherapy fails in phase 2 trial French biotech developing cancer immunotherapy with BMS.
News Opdivo still clear immunotherapy leader despite Keytruda gai... Immunotherapy takes on rivals from Roche and BMS.
News Pfizer looks to M&A after results disappointment Pfizer is looking to deals to keep investors onside after a disappointing set of Q4 results.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
